Sinohealth Holdings Ltd (2361) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Sinohealth Holdings Ltd HK$4.42, price HK$4.09, upside +8.1%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Sinohealth Holdings Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
51‑month range HK$1.94 – HK$6.33 · fair‑value band HK$2.94 – HK$6.27 · the HK$4.09 price screens below the HK$4.42 fair value. Dashed = 300-day average. As of Sep 27, 2026.
Follow Sinohealth Holdings in your weekly email
Every Wednesday you see whether Sinohealth Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sinohealth Technology Holdings Limited provides healthcare solutions for sales and marketing needs of medical product manufacturer clients in Mainland China and internationally.
Show more
Sinohealth Technology Holdings Limited provides healthcare solutions for sales and marketing needs of medical product manufacturer clients in Mainland China and internationally. It engages in the research and development, and provision of data insight solutions, data-driven publications and events, and software as a service (SaaS) products; research and development, and operation of Smart Medical Cloud under the business line of SaaS products; management of marketing and promotion services of medicine; operation of SaaS products; provision of internet information and internet data center services; production and publication of videos; and foreign-related market research business. The company also offers precision marketing solutions; and consulting and marketing services. It serves various fields, such as pharmaceutical industry, retail pharmacies, and physical examination and hospitals. Sinohealth Technology Holdings Limited was formerly known as Sinohealth Holdings Limited and changes its name to Sinohealth Technology Holdings Limited in February 2026. The company was founded in 2007 and is headquartered in Guangzhou, China.
Stock analysis
Sinohealth Holdings Ltd (2361) currently trades at HK$4.09, while our model-based Fair Value estimate is HK$4.42, so the stock looks roughly fairly valued today (gap 7.5%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of HK$4.56 per share, and 14 of the 26 models we run sit above the HK$4.09 price.
Bear case: the Asset-Based group reads lowest at HK$1.45, and 12 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$2.94 (bear) to HK$6.27 (bull), the price of HK$4.09 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Sinohealth Holdings Ltd reported revenue of 419M CNY in FY2025 versus 324M CNY in FY2021, a compound +6.6%/yr. Reported net income was 93.4M CNY in FY2025, compounding +4.3%/yr from FY2021.
Key figures
Market cap HK$2.0B (≈ $260M) · P/E ratio 20.8 · P/S ratio 4.64 · EPS (TTM) HK$0.0600 · Dividend yield 1.6% · Net margin 22.3% · Return on equity 12.9% · Return on assets (EBIT) 13.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 8%, 2361 screens cheaper than that median.
Fair Value models
Bear HK$2.94Fair Value HK$4.42Bull HK$6.27
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+3.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+10.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.7%
Dividend (yield on the price)1.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.38% → 25%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+11.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +9.3% a year for the price.
Compare Sinohealth Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 129 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+8.1% · Above median
Profitability
Return on equity (TTM)12.9% · Top 25%
Return on assets6.8% · Top 25%
Net margin (TTM)22.3% · Top 25%
Operating margin (TTM)27.8% · Top 25%
Growth and dividend
Revenue growth11.0% · Above median
Dividend yield (TTM)1.6% · Below median
Valuation Multiplesvs Health Information Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sinohealth Holdings Ltd (2361) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of HK$4.42 versus a price of HK$4.09, about +8% upside (fairly valued).
What is the fair value of 2361?
Our model-based fair value for Sinohealth Holdings Ltd is HK$4.42 (as of Sep 27, 2026), built from audited fundamentals. The current price: HK$4.09.
What is the quality score of 2361?
Sinohealth Holdings Ltd has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sinohealth Holdings Ltd (2361)?
Our model-based price target is the fair value of HK$4.42 (as of Sep 27, 2026) from 26 valuation models. Cautious scenario HK$2.94, optimistic scenario HK$6.27. It is a calculation from audited fundamentals, not an analyst target.
What is the Sinohealth Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$4.42, about +8% upside versus a price of HK$4.09 (fairly valued). Cautious scenario HK$2.94, optimistic scenario HK$6.27. The calculation is refreshed regularly with new filings.
What is the revenue of Sinohealth Holdings Ltd (2361)?
Sinohealth Holdings Ltd reported trailing-twelve-month revenue of about 419M CNY (latest available figure, as of Sep 27, 2026).
Does Sinohealth Holdings Ltd pay a dividend?
Sinohealth Holdings Ltd currently shows a dividend yield of about 1.57% relative to its recent price (as of Sep 27, 2026).
What growth is priced into Sinohealth Holdings Ltd (2361)?
For today's price to be fair in a discounted-cash-flow model, Sinohealth Holdings Ltd would have to grow free cash flow by +11.2 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.7 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of 2361 use?
Our models discount Sinohealth Holdings Ltd at 13.3 %: a base by market capitalisation (micro), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sinohealth Holdings Ltd that is +11.2 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Sinohealth Holdings Ltd (2361) delivered so far?
Over the past 5 years revenue at Sinohealth Holdings Ltd grew +15.7 % a year. The price currently implies +11.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sinohealth Holdings Ltd (2361) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Sinohealth Holdings Ltd (+11.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sinohealth Holdings Ltd (2361)?
The free-cash-flow yield on the price is 4.67 %: that much free cash flow Sinohealth Holdings Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sinohealth Holdings Ltd (2361)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sinohealth Holdings Ltd it is HK$4.42 per share (as of Sep 27, 2026), against a price of HK$4.09. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Sinohealth Holdings Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, 2361 trades below its calculated fair value: price HK$4.09, fair value HK$4.42, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2361?
No. The price is what the market pays today (HK$4.09); the fair value is what the company's own numbers justify (HK$4.42). For Sinohealth Holdings Ltd the two are HK$0.3320 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sinohealth Holdings Ltd worth?
The market values Sinohealth Holdings Ltd at about HK$2.0B (market capitalisation, as of Sep 27, 2026). Per share that is HK$4.09; our models calculate a fair value of HK$4.42 per share.
What do the bullish and bearish scenarios say about 2361?
Our models span a range for Sinohealth Holdings Ltd: cautious scenario HK$2.94, base HK$4.42, optimistic HK$6.27 per share (as of Sep 27, 2026, price HK$4.09). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2361?
Sinohealth Holdings Ltd trades at a price-to-earnings ratio of 20.8 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$4.42 is built from several models across several years. Other multiples: PEG 4.2, P/B 2.3, P/S 4.1, EV/EBITDA 15.9.
What is the PEG ratio of 2361?
The PEG ratio of Sinohealth Holdings Ltd is 4.21 (P/E divided by earnings growth, as of Sep 27, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Sinohealth Holdings Ltd (2361)?
Balance-sheet figures for Sinohealth Holdings Ltd (as of Sep 27, 2026): return on equity 12.9%. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 2361 from its 52-week high?
Sinohealth Holdings Ltd trades at HK$4.09, about 26% below its 52-week high of HK$5.51 and 15% above the low of HK$3.55 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of HK$4.42 is for.
Which stocks are comparable to Sinohealth Holdings Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sinohealth Holdings Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price HK$4.09, calculated fair value HK$4.42 (+8%), Quality Score 74/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2361 calculated?
We run Sinohealth Holdings Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$4.42, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.7 % above its aggregate fair value. Sinohealth Holdings Ltd currently trades 8 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sinohealth Holdings Ltd (2361)?
The closing price on Sep 30, 2026 was HK$4.09. Our model-based fair value is HK$4.42, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sinohealth Holdings Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (HK$2.94 to HK$6.27) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Sinohealth Holdings Ltd
How large is the market capitalisation of Sinohealth Holdings Ltd (2361)?
The market capitalisation of Sinohealth Holdings Ltd is HK$2.0B (≈ $260M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sinohealth Holdings Ltd (2361)?
The price-to-sales ratio of Sinohealth Holdings Ltd is 4.64 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sinohealth Holdings Ltd (2361)?
Earnings per share at Sinohealth Holdings Ltd are HK$0.0600 (price ÷ EPS = P/E 20.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sinohealth Holdings Ltd (2361)?
The dividend yield of Sinohealth Holdings Ltd is 1.6% (payout 107%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sinohealth Holdings Ltd (2361)?
The net margin of Sinohealth Holdings Ltd is 22.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sinohealth Holdings Ltd (2361)?
The return on equity (ROE) of Sinohealth Holdings Ltd is 12.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sinohealth Holdings Ltd (2361)?
On an EBIT basis the return on assets of Sinohealth Holdings Ltd is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sinohealth Holdings Ltd (2361)?
The operating margin of Sinohealth Holdings Ltd is 27.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sinohealth Holdings Ltd (2361)?
Revenue at Sinohealth Holdings Ltd is growing +11.0% versus a year earlier (3y avg +5.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sinohealth Holdings Ltd (2361)?
Earnings per share at Sinohealth Holdings Ltd are growing −19.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Sinohealth Holdings Ltd in the live analysis
One click puts Sinohealth Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
